Figure 2 | Scientific Reports

Figure 2

From: Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients

Figure 2

Kaplan–Meier plots for local tumor recurrence-free survival, overall recurrence-free survival and progression free survival after TACE according to metformin therapy. Local and overall recurrent-free survivals were analyzed in patients with complete response after initial TACE (A and B; n = 90), and the progression-free survival was calculated in overall patients (C; n = 163). The metformin group showed a significantly reduced local recurrence rate than the control group (A), but the overall recurrence was not different between the two groups (B). Progression-free survival was not different between control and metformin group, either (C). DM without metformin, patients with T2DM not treated with metformin; DM with metformin, patients with T2DM treated with metformin. HCC hepatocellular carcinoma, DM diabetes mellitus.

Back to article page